Buprenorphine for Office-based Practice: Consensus Conference Overview

American Journal on Addictions

Volumn 13, Issue SUPPL. 1, 2004, Pages

  Kosten, Thomas R ^a   Fiellin, David A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALOXONE;

CONFERENCE PAPER; CONSENSUS; DETOXIFICATION; GENERAL PRACTICE; HEALTH CARE ACCESS; MENTAL HEALTH SERVICE; OPIATE ADDICTION; PRESCRIPTION; PSYCHIATRIST; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; BUPRENORPHINE; COMMUNITY HEALTH SERVICES; CROSS-CULTURAL COMPARISON; DIFFUSION OF INNOVATION; FAMILY PRACTICE; HEROIN DEPENDENCE; HUMANS; NARCOTIC ANTAGONISTS; NARCOTICS; OFFICE VISITS; OPIOID-RELATED DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHIATRY; TREATMENT OUTCOME; UNITED STATES;

EID: 2342628601     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1080/10550490490440744     Document Type: Conference Paper

References (3)

1. Fiellin DA, Barthwell AG. Center for Substance Abuse Treatment. Guideline development for office-based pharmacotherapies for opioid dependence. Journal of Addictive Diseases. 2003; 22(4):109-120.
2. Nowak SN, Singh R, Clarke A, Campbell E, Jaber LA. Metabolic control and adherence to American Diabetes Association practice guidelines in a pharmacist-managed diabetes clinic. Diabetes Care. 2002;25(8):1479.
3. Borenstein JE, Graber G, Saltiel E, et al. Physician-pharmacist co-management of hypertension: a randomized, comparative trial. Pharmacotherapy. 2003;23(2):209-216.